Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

PURPOSE: The CLEOPATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel. Paclitaxel given once per week is effective and less toxic than docetaxel. We performed...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Dang, Chau, Iyengar, Neil, Datko, Farrah, D'Andrea, Gabriella, Theodoulou, Maria, Dickler, Maura, Goldfarb, Shari, Lake, Diana, Fasano, Julie, Fornier, Monica, Gilewski, Theresa, Modi, Shanu, Gajria, Devika, Moynahan, Mary Ellen, Hamilton, Nicola, Patil, Sujata, Jochelson, Maxine, Norton, Larry, Baselga, José, Hudis, Clifford
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2015
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747317/
https://ncbi.nlm.nih.gov/pubmed/25547504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.1745
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk